http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-100532381-C
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6a3911dfea2a0f7b93517edb324d243d |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-496 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D417-12 |
| filingDate | 2008-05-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2009-08-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2423c5975df40eeacce4ed153e79fe1f |
| publicationDate | 2009-08-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-100532381-C |
| titleOfInvention | Antineoplastic compound, medicament composition and use thereof |
| abstract | The invention relates to an anti-tumor compound, the pharmaceutical composition thereof and the application thereof, particularly an anti-tumor compound shown as the formula (I) or pharmaceutically acceptable salt thereof, solvate thereof, polymorph thereof, enantiomer thereof or racemic mixture thereof; the pharmaceutical composition thereof, the application in the preparation of antitumor drugs, and the preparation method thereof. The compounds can be used as the prodrug of Dasatinib to produce Dasatinib by enzymolysis. The compounds interact with intestinal protein transporters (such as PEPT1 or PEPT2) so that the compounds can be easily absorbed in an intestinal tract in comparison with the Dasatinib to generate higher Dasatinib bioavailability. |
| priorityDate | 2008-05-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 191.